Endologix AFX2 Graft Risk Information Updated in FDA-Approved Labeling
The FDA is requiring a post-market study by Endologix to determine AFX2 Graft System risks
The FDA is requiring a post-market study by Endologix to determine AFX2 Graft System risks
This is the latest in a string of stent graft system warnings by the FDA, due to the risk of potentially fatal endoleaks.